2025-12-31 - Analysis Report
Here's an analysis of Eli Lilly and Co (LLY) based on the provided data, broken down into sections for clarity.

**1) Return Rate Comparison and Analysis**

*   **Company Overview:** Eli Lilly and Co (LLY) is a global pharmaceutical company focused on discovering, developing, and marketing human pharmaceuticals.
*   **Cumulative Return:**
    *   LLY: 308.74%
    *   VOO (S&P 500): 102.21%
*   **Divergence:** 204.8 (Relative Divergence: 84.5)

**Analysis:** LLY has significantly outperformed the S&P 500. A cumulative return exceeding S&P 500 by ~200% represents substantial outperformance. The relative divergence of 84.5 suggests that the outperformance is near the upper end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis Table:**

| Year      | CAGR    | MDD   | Alpha  | Beta   | Cap(B) |
| --------- | ------- | ----- | ------ | ------ | ------ |
| 2015-2017 | 11.0%   | 76.1% | -17.0% | -0.0   | 75.7   |
| 2016-2018 | 39.0%   | 68.9% | 24.0%  | -0.0   | 103.7  |
| 2017-2019 | 41.0%   | 68.9% | 19.0%  | 0.4    | 117.8  |
| 2018-2020 | 34.0%   | 79.8% | 10.0%  | 0.4    | 151.4  |
| 2019-2021 | 53.0%   | 79.8% | 7.0%   | 0.5    | 247.6  |
| 2020-2022 | 64.0%   | 79.8% | 65.0%  | 0.4    | 328.0  |
| 2021-2023 | 125.0%  | 78.9% | 124.0% | 0.2    | 522.6  |
| 2022-2024 | 134.0%  | 81.2% | 113.0% | 0.2    | 692.1  |
| 2023-2025 | 200.0%  | 83.5% | 133.0% | 0.2    | 968.0  |

*   **CAGR:** The Compound Annual Growth Rate shows consistently strong growth, accelerating significantly in recent periods.
*   **MDD:** The Maximum Drawdown is relatively high, indicating significant price volatility and potential for losses.
*   **Alpha:** The Alpha is generally positive and increasing, indicating the stock is generating returns independent of the market. Notably high Alpha in recent years suggests the company's specific strategies/products are driving growth.
*   **Beta:** The Beta is low (around 0.2-0.5), suggesting LLY's price movements are less correlated with the overall market, offering diversification benefits. A Beta of less than one shows it is less sensitive to market movements than the S&P 500.
*   **Cap(B):** This is the market capitalization. It shows the company has grown immensely over the periods.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 1079.75
*   **Last Market Data:**
    *   Price: 1079.75
    *   Previous Close: 1078.73
    *   Change: 0.09
*   **Moving Averages:**
    *   5-day SMA: 1076.97
    *   20-day SMA: 1042.203
    *   60-day SMA: 960.5238

**Analysis:** The stock price is currently trading above all three moving averages, which suggests an uptrend. The short-term moving average (5-day) is very close to the current price, while the longer-term moving averages (20-day and 60-day) are significantly lower, further indicating recent upward momentum. The small change from the previous close indicates stability today, but monitoring further price action is crucial.

**3) Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 82.95 (Overbought)
*   **PPO:** -0.0633
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent Divergence Change:** 1.3 (+) (Short-term Increase)
*   **Expected Return:** 49.3% (long-term)

**Analysis:**

*   The MRI score indicates a favorable investment environment according to this specific indicator.
*   The RSI is in overbought territory, suggesting the stock may be due for a pullback or consolidation.
*   The PPO, while very slightly negative, gives little additional signal on its own. Combining with the RSI suggests a possible pullback.
*   The Hybrid Signal suggests a strong buy signal.
*   The positive divergence change indicates short-term upward momentum.
*   The high expected return suggests strong future growth potential compared to the S&P 500.

**4) Recent News & Significant Events**

*   **Weight-loss pill pricing and insider activity:** The stock's movement is linked to discussions around weight-loss drug pricing and insider filings.
*   **Stock Split Candidate:** Speculation about a potential stock split in 2026.
*   **Option Activity:** High option activity suggests increased investor interest and potential volatility.
*   **Analyst Coverage:** Mentions in articles about stocks to watch imply ongoing analyst attention.
*   **Institutional Ownership:** Reports of J.L. Bainbridge & Co. Inc. acquiring shares indicate institutional confidence.

**Analysis:** The news headlines suggest several key themes:

*   **Obesity Drug Focus:** Eli Lilly's weight-loss drugs are a major driver of investor interest. Pricing and market dynamics in this sector are closely watched.
*   **Potential Stock Split:** The possibility of a stock split can be a positive catalyst, often leading to increased demand from retail investors.
*   **Institutional Confidence:** Institutional buying reinforces the positive outlook for the stock.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.70)
*   **Opinions:** 27
*   **Target Price:** Average: 1093.22 / High: 1500.00 / Low: 770.00

**Analysis:** The analyst consensus is strongly bullish, with a "Buy" rating and a significant number of opinions. The average target price suggests only a slight upside from the current price, while the high target price indicates some analysts are very optimistic.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
| ---------- | ---- | --------- |
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3  | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

**Analysis:** The earnings table shows a clear trend of increasing revenue and EPS. Note there are 2 different values given for 2025-10-30. Assuming this is a typo and the second listing is meant to be another date, the data clearly shows the revenue and profit increasing for LLY. The growth in recent quarters is substantial.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| ------------ | ---------- | --------------- |
| 2025-09-30   | $17.60B   | 82.91%          |
| 2025-06-30   | $15.56B   | 84.27%          |
| 2025-03-31   | $12.73B   | 82.53%          |
| 2024-12-31   | $13.53B   | 82.24%          |
| 2024-09-30   | $11.44B   | 81.02%          |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
| ------------ | ---------- | -------- |
| 2025-09-30   | $23.79B   | 23.46%   |
| 2025-06-30   | $18.27B   | 30.98%   |
| 2025-03-31   | $15.76B   | 17.50%   |
| 2024-12-31   | $14.19B   | 31.07%   |
| 2024-09-30   | $14.24B   | 6.81%    |

**Analysis:**

*   **Revenue and Profitability:** Consistent revenue growth is evident, along with very high and stable profit margins.
*   **Capital and Profitability:** Equity is increasing, and ROE (Return on Equity) is generally high, indicating efficient use of shareholder equity to generate profits. The ROE fluctuates quarter to quarter, but maintains a good range.

**7) Comprehensive Analysis (Summary)**

Eli Lilly and Co (LLY) presents a strong investment case based on the provided data:

*   **Exceptional Performance:** LLY has significantly outperformed the S&P 500, driven by company-specific factors (high Alpha).
*   **Strong Financials:** The company exhibits consistent revenue growth, high profit margins, and efficient use of equity (high ROE).
*   **Positive Momentum:** Recent price action is positive, supported by moving averages and short-term divergence.
*   **Growth Drivers:** The focus on obesity drugs and the potential stock split are positive catalysts.
*   **Analyst Confidence:** Analysts have a bullish outlook, supported by institutional ownership.
*   **High Volatility:** The Maximum Drawdown indicates the stock can experience significant price swings.
*   **Overbought Condition:** The RSI indicates the stock might be overbought in the short term, and some profit-taking or a pullback may occur.

**Overall:** LLY appears to be a fundamentally strong company with significant growth potential. The high growth and recent news events are exciting, but the overbought RSI rating suggests watching out for a short term downturn.

**Disclaimer:** *This analysis is based solely on the provided data and does not constitute financial advice. Investors should conduct their own due diligence and consider their personal investment objectives and risk tolerance before making any investment decisions.*


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.